Salvatore, Lisa
 Distribuzione geografica
Continente #
NA - Nord America 913
EU - Europa 407
AS - Asia 190
AF - Africa 6
Totale 1.516
Nazione #
US - Stati Uniti d'America 907
IT - Italia 104
SG - Singapore 93
SE - Svezia 89
DE - Germania 48
CN - Cina 46
FI - Finlandia 35
IE - Irlanda 35
FR - Francia 25
ID - Indonesia 24
AT - Austria 22
GB - Regno Unito 11
RU - Federazione Russa 10
HK - Hong Kong 8
CA - Canada 6
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
IN - India 6
IR - Iran 6
BE - Belgio 5
RO - Romania 4
ES - Italia 3
LT - Lituania 3
NL - Olanda 2
TH - Thailandia 2
VA - Santa Sede (Città del Vaticano) 2
CH - Svizzera 1
GE - Georgia 1
GR - Grecia 1
IL - Israele 1
KZ - Kazakistan 1
PL - Polonia 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 1.516
Città #
Ashburn 495
Chandler 152
Singapore 75
Rome 42
Dublin 35
Helsinki 32
Jakarta 24
Vienna 21
New York 20
Boston 17
Marseille 16
Princeton 15
Milan 13
Munich 13
Los Angeles 12
Cattolica 10
Falkenstein 10
Beijing 9
Chicago 8
Hong Kong 8
Moscow 8
Bremen 7
San Mateo 7
Wilmington 7
Abidjan 6
Columbus 6
Toronto 6
Bari 5
London 5
Redmond 5
Brdo 4
Brussels 4
Kish 4
Washington 4
Boardman 3
Hounslow 3
Lappeenranta 3
Palermo 3
Piacenza 3
Rocca Massima 3
Timisoara 3
Amsterdam 2
Arezzo 2
Bangkok 2
Barcelona 2
Bologna 2
Brno 2
Frankfurt am Main 2
Guangzhou 2
Hyderabad 2
Legnano 2
Markgröningen 2
Mathura 2
Menlo Park 2
Phoenixville 2
Pune 2
Romainville 2
Santa Clara 2
Seattle 2
Acton 1
Almaty 1
Amaseno 1
Andover 1
Anyang 1
Ardabil 1
Augusta 1
Bern 1
Brooklyn 1
Buffalo 1
Cambridge 1
Comiso 1
Deva 1
Esslingen am Neckar 1
Fairfield 1
Fremont 1
Fuyang 1
Huizhou 1
Isernia 1
Karlsruhe 1
Kilburn 1
Lanzhou 1
Linfen 1
Linyi 1
Mechelen 1
Nanjing 1
Nanyang 1
New Orleans 1
Novokuznetsk 1
Nuremberg 1
Paris 1
Pasadena 1
Piraeus 1
Quanzhou 1
Redwood City 1
Richmond 1
Riyadh 1
Saint-maur-des-fossés 1
Secaucus 1
Shanghai 1
Southwark 1
Totale 1.203
Nome #
Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection 511
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center 78
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy 74
Management of single pulmonary metastases from colorectal cancer: State of the art 73
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 69
Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis 67
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report 62
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 58
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies 53
Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies 46
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 46
MetaLiverCat: the NAFLD/NASH multidisciplinary board at Fondazione Policlinico Gemelli IRCCS 41
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers 41
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial 41
Management of patients with early-stage colon cancer: Guidelines of the Italian Medical Oncology Association 37
PTEN in colorectal cancer: Shedding light on its role as predictor and target 37
Activity and safety of cetuximab plus modified folfoxiri followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer a randomized phase 2 clinical trial 30
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients 29
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 28
Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies 26
The impact of the histological classification of ampullary carcinomas on long-term outcomes after pancreaticoduodenectomy: a single tertiary referral center evaluation 22
The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience 22
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis 21
Predicting In-Hospital Mortality in COVID-19 Older Patients with Specifically Developed Scores 18
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C 18
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 6
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 1
Totale 1.555
Categoria #
all - tutte 7.955
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.955


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 0 0 1 0 1 0 3 0
2020/202110 0 0 0 0 0 0 0 0 0 5 5 0
2021/2022128 7 2 0 12 3 3 2 16 4 11 35 33
2022/2023430 40 45 35 68 36 52 26 27 41 14 16 30
2023/2024750 10 48 27 22 17 38 242 255 2 14 37 38
2024/2025227 12 11 56 32 53 40 23 0 0 0 0 0
Totale 1.555